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compatibilizers as well as drug struc-
ture specific solubilizers or enzymatically 
activable glues.[15–24] Recently, the direct 
translation of a peptide sequence toward 
peptide-structure related precision poly-
mers was demonstrated.[25] The peptide 
was identified by combinatorial means for 
drug hosting and solubilization of meta-
tetra(hydroxyphenyl)-chlorin (m-THPC) as 
one of the promising second generation 
photosensitizers for the photodynamic 
cancer therapy.[26] The peptide sequence 
was effectively mimicked by mono-
disperse precision segments based on 
either heptamer oligo(2-substituted α-hydroxyl acid)s or pen-
tamer oligo(N-substituted acrylamide)s.[25] Those precision 
segments exhibited discrete side-chain sequences, which 
match the peptide side-chains in functionality and order. The 
approach proved to be valid, as the corresponding poly(ethylene 
glycol) (PEG) conjugates of those precision segments mim-
icked the drug solubilizer properties of the parent peptide-PEG 
conjugate, by reaching up to 40% higher payloads and showing 
more desired drug release profiles. These precision polymer 
platforms were ideal for the exploration of peptidomimetic pre-
cision segments, as peptides show chemical similarities with 
oligo(N-substituted acrylamide)s and structural similarities to 
oligo(2-substituted-α-hydroxy acid)s. Within the last decade, 
sequence-defined polymers have been set into the focus of 
polymer chemistry,[27–31] because this class of macromolecules 
enables envisioning the realization of highly selective func-
tions as found within information-rich biomacromolecules 
like RNA/DNA, oligosaccharides and peptides/proteins.[32,33] 
Meanwhile, elegant and efficient means have been established 
to synthesize precision polymers, exploiting both solid-phase 
supported and solution synthesis routes based on a variety of 
backbone chemistries and rapidly growing sets of fully syn-
thetic monomer libraries.[34–38] While some precision polymers 
are closely related to existing classes of biomacromolecules like 
for instance peptoids or nucleotide resembling polymers,[34,39] 
several precision platforms explore more widely the chemical 
space available for backbone and side chain chemistries.[40–42] 
Among the latter, thiolactone-based oligo(amide-urethane)
s have shown to be a versatile precision polymer platform.[43] 
Du Prez et al. introduced the type of polymer and described a 
route by solid phase supported submonomer synthesis.[44] The 
two step synthesis protocol relies on thiolactone (Tla)/Michael 
chemistry and made a large set of monomers available by 
reacting different acrylates in the second synthesis step of the 
reaction cycle.[42] Previously, a combinatorial strategy was dem-
onstrated to screen an one-bead one-compound (OBOC) library 
Copy Peptide Sequences
Functional sequences of monodisperse, sequence-defined oligo(amide-urethane)
s are designed based on a peptide sequence as blueprint. The translation of a dis-
crete side-chain functionality sequence from a known peptide-based solubilizer of 
the photosensitizer meta-tetra(hydroxyphenyl)-chlorin, into a non-peptidic preci-
sion polymer backbone is demonstrated. The resulting peptidomimetic precision 
polymers retain the functions of the parent peptide sequence, showing analogues 
sensitivity toward single monomer mutations/exchanges and even exceeding the 
parent peptide equivalent by reaching up to 69% higher payload capacities and 
more favored release kinetics.
Rebuilding functional minimal sequences of proteins with 
non-α-amino acid building blocks proved to be one of the 
potent strategies to access functional peptidomimetics.[1,2] 
The approach was utilized for the realization of synthetic ana-
logues based on biologically active peptides like antimicro-
bial peptides,[3,4] cell penetrating peptides,[5,6] peptide-based 
hormones,[7] or HIV-Tat nuclear localization signals.[8,9] Par-
ticularly oligopeptides offer a suitable platform as sequence–
structure–function relationships are often well understood or 
can be predicted by computational simulation. Moreover, (bio)
combinatorial approaches such as split and mix libraries, phage 
display biopanning or peptide array technologies, as well as 
mass spectrometry sequencing and interaction profiling are 
routinely available for the peptides, holding the promise to 
reveal functional sequences.[10–14] Those established tools ena-
bled the exploitation of peptides in materials sciences, where 
peptide applications span from programmable nanostructure 
formation for biomedicine or nanoelectronics, to the direc-
tion of hierarchically ordered hybrid materials, to bioactive 
material interfaces, surface specific coatings, material specific 
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of oligo(amide-urethane) precision polymers against m-THPC 
to identify sequence domains with high binding capacities.[45] 
Corresponding PEG-conjugates result in precision formulation 
additives, where the sequence proved to sensitively influence 
the m-THPC hosting and release properties.
While the combinatorial OBOC route proved to reveal func-
tional precision segments, the direct translation of oligopep-
tides to precision polymer backbones by monomer-to-monomer 
mapping of the peptide side-chain functionalities appears to be 
more straightforward and demands less synthetic efforts.
Herein, we investigate the scope to broaden the strategy of 
direct sequence translation from a functional peptide into a 
sequence of a precision polymer that is chemically and struc-
turally unrelated to a peptide. The m-THPC hosting peptide 
domain was taken as template and a monodisperse precision 
polymer from the type of thiolactone-based oligo(urethane-
amide)s was synthesized as a PEG-conjugate. The drug hosting 
and release properties of a set of PEG-precision conjugates, 
which exhibited single side sequence mutations, has been ana-
lyzed and the relevant properties were compared to those of the 
parent peptide-PEG conjugate.
The previously analyzed peptide-PEG conjugate QFFLFFQ-
PEG solubilized m-THPC and reached payload capacities of up 
to 1:3.3 (molar ratio drug:carrier).[26] The systematic alanine 
substitution (Ala-scan) revealed the hydrophobic core domain 
FFLFF as the segment of importance for drug hosting.[25,46] 
While an exchange of the polar Gln1 or Gln7 residues 
increased the capacity by up to 39%, the substitution of the cen-
tral residue Leu4 by Val or Ala residues reduced the payload 
dramatically by up to 92%.[25] Moreover, the polar peptidic back-
bone and the amide side chain functionalities of the flanking 
Gln residues were required to accelerate the drug release.[25,46] 
A removal or substitution of both polar Gln1 and Gln7 residues 
lead to undesired slow release kinetics, whereas the exchange of 
only one Gln residue preserved the fast release profile. Taking 
those sequence related properties of the peptide-PEG conjugate 
into account, a set of oligo(amide-urethane) precision polymers 
was designed (Figure 1). The target sequence originated from 
monomer-to-monomer mapping, by translating the relevant 
peptide side-chain functionality-sequence of a minimal binding 
motif into the precision polymer backbone (Figure 1). The 
flanking Gln-analogue residues have been not included into 
the sequence design, as it was hypothesized that the extended 
polar backbone structure of the oligo(amide-urethane) preci-
sion segment provides sufficient polarity to counterbalance 
their removal.
The precision polymer set was synthesized by the iterative 
thiolactone (Tla)/Michael submonomer synthesis on a PEG 
Macromol. Biosci. 2020, 20, 1900244
Figure 1. Representation of the sequence transfer strategy, translating a functional peptide-PEG conjugate after sequence minimization into a cor-
responding PEG-conjugated precision sequence (top/middle) and MALDI-TOF MS analysis data of the PEG-block-oligo(amide-urethane) precision 
polymers [Tla/Michael]FFLFF-PEG, [Tla/Michael]FFVFF-PEG, and [Tla/Michael]FFAFF-PEG (bottom, from left to right; for detailed assignments, see Sup-
porting Information).
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preloaded poly(styrene) resin (PAP resin) to directly obtain (Tla/
Michael)-PEG conjugates with PEG blocks of Mn = 3000 Da 
and Đ = 1.04.[47] Due to the polarity of the support an adapted 
synthesis protocol had to be applied, where isocyanate thiol-
actone coupling and aminolysis steps have been enforced.[48] 
The platform of oligo(amide-urethane) precision polymers, 
allows to define the side chain functionalities by employing 
different acrylic acid esters in the presence of 2-aminoethanol 
for the aminolysis/Michael thiol-ene reaction step. Thus, 
benzyl acrylate, isobutyl acrylate, isopropyl acrylate, and methyl 
acrylate build up the analogue monomer alphabet to mimic 
Phe, Leu, Val, and Ala, respectively (Figure 1). A [Tla/Michael]-
PEG conjugate, with a side chain sequence based on the core 
segment of the parent peptide FFLFF was synthesized ([Tla/
Michael]FFLFF-PEG). Moreover, the two single point mutations 
in the central position realized in [Tla/Michael]FFVFF-PEG and 
[Tla/Michael]FFAFF-PEG a systematic reduction of the hydropho-
bicity by exchanging the Leu3-analogue residue to Val- or Ala-
analogues (Figure 2, Supporting Information).
The set of PEGylated precision polymers was cleaved 
from the support and 1H-NMR, IR as well as MALDI-TOF 
MS analyses verified the structural and chemical identity of 
the compounds (cf. Figure 1; Supporting Information). All 
samples were readily soluble in aqueous media. M-THPC 
loading experiments were performed by following enforced 
drug loading procedures.[26] Interestingly, all three con-
jugates [Tla/Michael]FFLFF-PEG, [Tla/Michael]FFVFF-PEG, 
and [Tla/Michael]FFAFF-PEG were able to reach higher payload 
capacities for m-THPC in comparison to their peptide-PEG 
analogues (Figure 2). The precision polymer PEG-conjugate 
[Tla/Michael]FFLFF-PEG that originated from the direct transla-
tion of the parent peptide, reached a payload of 1:1.2 (molar 
ratio drug:carrier), which is about 69% higher compared to the 
value found by the peptide-PEG conjugate under similar con-
ditions. For comparability reasons, the capacity values shown 
in Figure 2, were normalized to the mass fraction of the func-
tional segment (peptide or oligo(amide-urethane)). The side 
chain spacing along the backbone of the precision segment is 
expected to be larger and the conformational freedom of the 
side chain and backbone is significantly higher compared to 
amino acids in the parent 7mer oligopeptide. This might enable 
the formation of a more optimized interface between the preci-
sion segment and the drug. The flexibility might reduce the for-
mation of “frustrated” segments that cannot participate in drug 
binding, which would explain the higher drug binding capacity 
of the precision segment compared to the peptide.
Comparing the drug loading capacities of the set of preci-
sion conjugates, which have single point mutations, revealed 
an obvious decrease between [Tla/Michael]FFLFF-PEG and 
both [Tla/Michael]FFVFF-PEG and [Tla/Michael]FFAFF-PEG by 
reaching payload capacities of 1:1.2, 1:3.1, and 1:3.0, respec-
tively (molar ratio drug:carrier) (Figure 2). Interestingly, 
peptide-PEG conjugates show also a high sensitivity of the 
m-THPC loading capacity on central Leu4 residue exchange by 
Val and Ala. In both, the [Tla/Michael]-PEG and the peptide-
PEG conjugates the payload reduces similarly by about 60%, 
if QFFLFFQ-PEG or [Tla/Michael]FFLFF-PEG were compared 
to QFFVFFQ-PEG or [Tla/Michael]FFVFF-PEG, respectively. 
The significantly affected payload capacity in the precision-
PEG system by the exchange of a single isobutyl to isopropyl 
side chain functionality remains remarkable. It should be 
noted, that the [Tla/Michael] segment compared to the peptide 
exhibits both a higher conformational flexibility and a higher 
weight fraction of the backbone structure versus the variable 
side chain functionalities. Where the parent peptide QFFLFFQ 
shows 42 wt% contributed by the backbone and 58 wt% by the 
side chains, the precision analogue [Tla/Michael]FFLFF exhibits 
77 wt% of a constant backbone structure and only 23 wt% 
result from the variable side chains. Hence, a change of side 
chain functionality is expected to have less impact on the 
precision system properties because only a minor fraction is 
changed. Moreover, the side chain functionality in the preci-
sion segment is not tightly coupled to the backbone structure 
due to an extended and flexible spacer. However, the reduction 
by –CH2– in only one side chain, lowers the payload capacity 
by 62%. Such an obvious effect is certainly surprising, but indi-
cates sharply defined sequence–property relationships as pre-
dicted for monodisperse oligomers. The reduction in payload 
is even more pronounced in the peptide system, lowering the 
capacity of QFFVFFQ-PEG to QFFAFFQ-PEG further by 58% 
to reach only 8%, of the capacity from the parent QFFLFFQ-
PEG conjugate. In contrast to this, a reduction cannot be found 
in the respective precision conjugates ([Tla/Michael]FFVFF-PEG 
versus [Tla/Michael]FFAFF-PEG), as the Val to Ala analogues 
reached rather similar capacities (Figure 2). This suggests that 
the found effect is not simply due to a decrease in volume frac-
tion of the hydrophobic segment and makes specific binding 
interactions between [Tla/Michael] domains and m-THPC 
likely.
Dynamic light scattering (DLS) measurements of the set of 
precision polymer conjugates were performed prior and after 
m-THPC loading to provide insights into the type of solubili-
zation (Figure 3). Monomodal size distributions of the drug 
loaded complexes with hydrodynamic radii (Rh) in the range 
of 42–55 nm and low polydispersity indices < 0.1 indicate 
the presence of well-defined colloidally stable aggregates in 
aqueous solution. The aggregate sizes are in a range to exclude 
discrete micelle formation and suggest the presence of more 
Macromol. Biosci. 2020, 20, 1900244
Figure 2. Drug loading capacities of PEG-conjugates with preci-
sion polymer or peptide segments are specified as normalized values 
to the masses of the functional segments (corresponding molar ratio 
drug:carrier are provided on top of each column).
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complex non-equilibrium structures. This was supported by 
cryo-transmission electron microscopy (cryo-TEM) analysis of 
a representative drug/solubilizer complex (cf. Figure S4, Sup-
porting Information). The cryo-TEM images of an aqueous 
solution of m-THPC/[Tla/Michael]FFAFF-PEG exhibit isotropic 
aggregates with rather homogeneous contrast distribution and 
reveal an average radius of about 50 nm, which agrees very well 
with the findings from DLS proving a Rh of 55 nm. Obviously, 
the DLS analysis results indicate that differences in loading 
capacity of the three [Tla/Michael]-PEG conjugates were not 
resulting from a dramatic change of the aggregate sizes. As 
the sizes of the drug/solubilizer complexes remain well below 
100 nm with relatively low polydispersity indices they appear 
suitable for biomedical applications, for example, for the photo-
dynamic cancer therapy.[49] In the absence of the drug, all preci-
sion polymer conjugates exhibit in dilute solutions multimodal 
size distributions (data not shown), which suggest the presence 
of dynamic, ill-defined aggregates. This could be expected for 
oligo(amide-urethane)-block-PEG copolymers, having the possi-
bility for various intermolecular interactions between the func-
tional segments.
It seems to be noteworthy, that [Tla/Michael]FFLFF-PEG 
shows even a higher drug payload capacity compared to the 
best performing candidate resulting from a recently described 
combinatorial screening of a library of sequences based on 
the same type of oligo(amide-urethane) precision polymers.[45] 
This can be rationalized by the presence of two benzyl dyads 
in [Tla/Michael]FFLFF-PEG, whereas the sequences found by 
the combinatorial approach exhibit only one benzyl dyad. From 
the peptide sequence analysis the importance of benzyl dyads 
to contribute to the payload capacity was indicated.[46] It should 
be emphasized, that the combinatorial screening was success-
fully identifying unknown high capacity binding sequences. 
However, as common in combinatorial approaches, several 
sequence candidates need to be tested to reveal the best per-
formers from the pool of screening results. In one-bead one-
compound library-screening assays, also secondary selection 
criteria like sequence solubility, segment self-aggregation or 
segment interactions with the support are relevant to modulate 
the availability of the supported sequences and influence the 
screening results.
Drug loading capacity constitutes only one of the important 
parameters for drug solubilization and transport. Particularly, 
the class of precision formulation additives offers the capability 
to fine-tune drug release kinetics, by controlling the drug-solu-
bilizer interactions precisely. This parameter could be included 
actively in the selection procedure.[50] As recently demonstrated 
in a 2D screening, peptide sequences can be selected for both 
high capacity drug binders and tailored drug release profiles. 
However, the QFFLFFQ originated from an earlier study and 
drug release kinetics could be analyzed by a fluorescence 
spectroscopy assay.[26] This enabled to follow the trans-solubi-
lization of m-THPC from drug/solubilizer complexes toward 
albumin (bovine serum albumin, BSA) as a blood plasma pro-
tein model. During the transfer of the drug from solubilizer 
complexes to BSA, the fluorescence activity and singlet oxygen 
production capability of m-THPC were regained.[26] In many 
drug delivery applications, a strong drug binding is required 
for effective drug transport.[51,52] Nonetheless, the concept 
of drug solubilizers profits from a transient binding and a 
rapid drug release to blood plasma proteins.[26] Those inbuilt 
biotransport systems, will be responsible for systemic distribu-
tion in a potential therapeutic application.[53,54] A fast release of 
m-THPC is beneficial for a rapid activation of the photosensi-
tizer to prevent adverse effects like extended light sensitivity of 
patients.[55]
Macromol. Biosci. 2020, 20, 1900244
Figure 3. Photosensitizer solubilization and release kinetics of m-THPC from oligo(amide-urethane)-PEG conjugate complexes. a) Schematic illustration 
of the trans-solubilization of m-THPC from colloidal drug/solubilizer complexes to albumins as blood plasma protein models, b) DLS analysis of the 
set of precision polymer conjugates prior and after m-THPC loading, and c) drug release kinetics from m-THPC/solubilizer complexes to bovine serum 
albumin (conditions: λex = 417 nm, λem = 653 nm, c[BSA] = 100 µm, c[m-THPC] = 0.1 µm; n.a. = not analyzable due to multimodal size distributions).
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Similarly, to the m-THPC/peptide-PEG complexes, the fluo-
rescence activity of m-THPC/[Tla/Michael]-PEG complexes 
was fully quenched, but fluorescence was regained after the 
addition of BSA. Hence, similar mechanisms can be antici-
pated, suggesting that BSA triggers the transsolubilization 
of the drug to form fluorescence active m-THPC/BSA com-
plexes. The release profiles of m-THPC from drug-loaded [Tla/
Michael]-PEG solubilizers showed a related type as compared 
to these, found in m-THPC/peptide-PEG complexes (Figure 3). 
The release kinetics of the parent m-THPC/QFFLFFQ-PEG 
complex were quite similar to those of the m-THPC/[Tla/
Michael]FFVFF-PEG and m-THPC/[Tla/Michael]FFAFF-PEG com-
plexes. The drug release from the m-THPC/[Tla/Michael]FFLFF-
PEG complex, where the directly copied precision sequence 
was utilized, appears to be faster and even more effective. 
While under these conditions ≈60% of the releasable drug was 
released from the m-THPC/[Tla/Michael]FFLFF-PEG complexes 
within 3 h, only ≈40% of the releasable drug was activated 
from m-THPC/QFFLFFQ-PEG complex with the parent pep-
tide solubilizers. Also, the half-release time (t1/2), where 50% 
of the releasable drug is activated, was more favorable in the 
precision system. While the m-THPC/[Tla/Michael]FFLFF-PEG 
complexes reached t1/2 of 2 h, the m-THPC/QFFLFFQ-PEG 
complexes had under comparable conditions a t1/2 of 4.5 h. 
Interestingly, both solubilizer systems, peptide-PEG and [Tla/
Michael]-PEG indicated similar sensitivity of the initial m-
THPC release rates on the central residue exchange (Figure 3; 
Table S1, Supporting Information). The sequence variants with 
Ala or Ala-analogue residues exhibit the highest initial release 
rates of m-THPC from the respective drug/solubilizer com-
plexes. This was followed by sequences with Leu/Leu-analogue 
residues, having lower and sequences with Val/Val-analogue 
residues exhibiting the lowest initial release rates. The correla-
tion between the respective sequence variants of both peptide 
and oligo(amide-urethane) segments is certainly notable. This 
analogy seems to be a remarkable finding, as the oligomer plat-
forms, which were compared in this study exhibit rather dis-
similar backbone chemistries, structures, and conformational 
dynamics. Nonetheless, the similar sensitivities of properties 
on sequence variations proved that the translation of side-chain 
functionality sequences across unrelated backbone platforms is 
feasible. Property trends can be transferred to the peptidomi-
metic polymers, even if, several factors at the molecular level 
are influencing the drug loading and release profiles within the 
kinetically controlled loading procedure and the interface con-
trolled trans-solubilization process.
In conclusion, the side chain functionality sequence of 
the functional peptide QFFLFFQ was translated into a preci-
sion polymer segment, based on monodisperse oligo(amide-
urethane)s ([Tla/Michael] precision polymer). The peptide has 
been selected recently by combinatorial means and the corre-
sponding peptide-PEG conjugate proved to be a capable solubi-
lizer for the photosensitizer m-THPC. The PEGylated precision 
segment [Tla/Michael]FFLFF-PEG not only retained properties of 
the parent QFFLFFQ-PEG conjugate, but reached 69% higher 
payload capacities as well as more desired drug release prop-
erties. Sets of peptide-PEG and [Tla/Michael]-PEG solubilizers 
were accessed by systematic sequence variations, substituting 
the central Leu/Leu-analogue residue by Val and Ala or their 
respective analogue residues. The study confirmed the pres-
ence of sharply defined sequence–property relationships in 
monodisperse functional segments. Remarkable analogies 
between the peptide-PEG and the corresponding [Tla/Michael]-
PEG conjugates sets were indicated by proving similar sensi-
tivity of the payload capacity on the central side chain alterna-
tion (e.g., Leu/Leu-analogue → Val/Val-analogue). Moreover, 
the [Tla/Michael]-PEG closely mimicked the behavior of the 
peptide-PEG by reaching the highest initial release rates of 
solubilized m-THPC with the Ala/Ala-analogue and showing 
a rate decrease in the order of Ala, Leu, and Val (analogues) 
residues. The translation of peptide side-chain sequences into 
backbones of precision polymers proved to assist the design 
of functional precision polymer sequences. The approach has 
been effectively expanded from precision polymers with back-
bone structure/chemistry that is closely related to peptides, 
toward peptide-unrelated precision polymer backbones that 
strongly differ in structure and chemistry. However, property 
testing will always be required to confirm the function as it can 
be expected that not only side-chain functionality sequences, 
but also backbone chemistry, structure, dimensions, and con-
formational dynamics have a strong contribution to constitute 
the final function and/or property in the precision polymers.
Experimental Section
Materials, instrumentation, experimental procedures, and analytical data 
are available in the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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